SCHEMBL446308

SCHEMBL446308

CCN(CC)C(=S)N(C)NC(=O)CS(=O)(=O)NN(C)C(=S)c1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 2/20 0.54
HSP90AB1 P08238 1/20 0.54
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
ALDH1A1 P00352 4/20 0.35
HPGD P15428 3/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
MAPT P10636 2/20 0.35
ABCC1 P33527 1/20 0.34
LMNA P02545 1/20 0.33
HSD17B10 Q99714 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
LIMK1 P53667 1/20 0.32
LIMK2 P53671 1/20 0.32
POLB P06746 1/20 0.32
KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL445766 0.95 HSP90AA1 (0.58) HSP90AA1HSP90AB1NPC1RAB9ASMN1; SMN2
SCHEMBL464655 0.89 HSP90AA1 (0.68) HSP90AA1HSP90AB1NPC1RAB9ASMN1; SMN2
SCHEMBL445761 0.85 HSP90AA1 (0.59) HSP90AA1HSP90AB1NPC1RAB9ASMN1; SMN2
SCHEMBL446362 0.83 HSP90AA1 (0.63) HSP90AA1HSP90AB1ALDH1A1HPGDL3MBTL1
SCHEMBL445596 0.82 HSP90AA1 (0.59) HSP90AA1HSP90AB1ALDH1A1HPGDL3MBTL1
SCHEMBL447212 0.82 HSP90AA1 (0.56) HSP90AA1HSP90AB1ALDH1A1HPGDL3MBTL1
SCHEMBL449281 0.81 HSP90AA1 (0.54) HSP90AA1HSP90AB1SMN1; SMN2ALDH1A1HPGD
SCHEMBL2473542 0.81 HSP90AA1 (0.48) HSP90AA1HSP90AB1NPC1RAB9ASMN1; SMN2
SCHEMBL448191 0.81 HSP90AA1 (0.53) HSP90AA1HSP90AB1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL446749 0.80 HSP90AA1 (0.59) HSP90AA1HSP90AB1NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8680100-B2 Sulfonylhydrazide compounds for treating proliferative disorders SYNTA PHARMACEUTICALS CORP. (US) 2014-03-25 US disclosed
US-8680100-B2 Sulfonylhydrazide compounds for treating proliferative disorders SYNTA PHARMACEUTICALS CORP. (US) 2014-03-25 US disclosed
US-20120065206-A1 COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS SYNTA PHARMACEUTICALS CORP. (US) 2012-03-15 US disclosed
US-20120065206-A1 COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS SYNTA PHARMACEUTICALS CORP. (US) 2012-03-15 US disclosed
EP-2370402-A2 COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS Synta Pharmaceuticals Corp. (US) 2011-10-05 EP disclosed
WO-2010065512-A2 COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS SYNTA PHARMACEUTICALS CORP. (US) 2010-06-10 WO disclosed
WO-2010065512-A2 COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS SYNTA PHARMACEUTICALS CORP. (US) 2010-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065206-A1 COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS PKD1, PKD2, PCNA HSP90AA1 2300/4885HSP90AB1 1711/4885NPC1 349/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.